Vimarsana
Biggest News Aggregation in the World

Page 45 - Between July News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between July. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between July Today - Breaking & Trending Today

Census data: 'Domestic out-migrants' driving Long Island exodus - Vimarsana News

Census data: 'Domestic out-migrants' driving Long Island exodus

The decade-slong trend of people leaving Long Island is part of a broader trend of New Yorkers leaving the state in pursuit of an affordable place to live, experts say. 

Somalia: Health Cluster Bulletin, February 2023 - Somalia - Vimarsana News

Somalia: Health Cluster Bulletin, February 2023 - Somalia

Situation Report in English on Somalia about Contributions, Coordination, Drought, Epidemic and more; published on 23 Mar 2023 by Health Cluster and WHO

WFP Guinea-Bissau Country Brief, July and August 2022 - Guinea-Bissau - Vimarsana News

WFP Guinea-Bissau Country Brief, July and August 2022 - Guinea-Bissau

Situation Report in English on Guinea-Bissau about Agriculture, Contributions and more; published on 30 Sep 2022 by WFP

From E&P reader nominations, here are the photojournalists we are saluting as 2022 "Shooting Stars" - Vimarsana News

From E&P reader nominations, here are the photojournalists we are saluting as 2022 "Shooting Stars"

Talented visual journalists take us inside a moment, or a series of them, communicating information and inspiring emotion — whether it’s through a single image or hours of video footage. Top-of-the-field news photographers and videographers are technicians, creative visionaries, astute observers and chroniclers of history. They capture stories frame by frame, appending narratives and scripts with visual complements. This inaugural class of Shooting Stars comes from small publications and large corporate entities.

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study - Vimarsana News

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

Data support the clinical use of fezolinetant as a non-hormonal treatment for vasomotor symptoms associated with menopause. The study was placebo-controlled for 12 weeks followed by a 40-week blinded extension to assess the maintenance of effect. Furthermore, the population studied was diverse and representative of the potential target population for fezolinetant therapy. Further characterisation of the benefit of fezolinetant on quality of life, including on symptoms of mood and sexual wellbeing, merits investigation.

Related Topics:
Between July